Voir la vidéo du What’s Up Daily de l’ESC 2020, réalisée par Nicolas Lellouche

Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). The recent international consensus report supports RFCA as a first-line therapy for VA in normal heart Ventricular Tachycardia (VT) and in structural heart VT after ineffective anti-arrhythmic drug (AAD) therapy.¹ Several groups have taken this further, proposing prophylactic VT ablation before implantable cardiac defibrillator (ICD) insertion; however this remains an area of debate...

Ventricular tachycardia (VT) results in significant morbidity, and in patients with structural heart disease (SHD) (including prior myocardial infarction) is associated with increased risk of sudden cardiac death (SCD).^{1 2} In myocardial infarction survivors the risk of SCD can be reduced with implantable cardioverter defibrillator (ICD) implantation.³ While ICDs are effective in terminating VT and aborting SCD, they do not prevent ventricular arrhythmias. Given that ICD shocks are associated with reduced quality of life and increased mortality,⁴ strategies are sought to prevent VT and minimise shocks...

Atrial fibrillation ablation is an effective and recognized therapy. However this technique is associated with a high rate of arrhythmia recurrences. Indeed the estimated rate of recurrence following paroxysmal AF ablation is up to 30% and up to 50% for persistent AF after one procedure. Arrhythmia recurrences following AF ablation are characterized according to the timing of recurrence and the type of arrhythmia recurrences...